Myeloperoxidase and risk of recurrence of atrial fibrillation after catheter ablation

Journal of Investigative Medicine

Volumn 61, Issue 4, 2013, Pages 722-727

  Li, Shuai Bing ^a   Yang, Fan ^a   Jing, Li ^a   Ma, Juan ^a   Jia, Ya Dan ^a   Dong, Shao Ying ^a   Zheng, Wei Feng ^a   Zhao, Luo Sha ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Atrial fibrillation; Catheter ablation; Myeloperoxidase; Recurrence

Indexed keywords

C REACTIVE PROTEIN; MYELOPEROXIDASE;

ADULT; ARTERY DIAMETER; ARTICLE; CATHETER ABLATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; PAROXYSMAL HEART ATRIUM FIBRILLATION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PULMONARY VEIN ISOLATION; RECURRENCE RISK; RECURRENT DISEASE;

EID: 84877881399     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3182857fa0     Document Type: Article

References (30)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.
2. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946-952.
3. Koitabashi T, Inomata T, Niwano S, et al. Paroxysmal atrial fibrillation coincident with cardiac decompensation is a predictor of poor prognosis in chronic heart failure. Circ J. 2005;69:823-830.
4. Boixel C, Fontaine V, Rücker-Martin C, et al. Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. J Am Coll Cardiol. 2003;42:336-344.
5. Marín F, Roldán V, Climent V, et al. Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1? Stroke. 2003;34:1181-1186.
6. Mukherjee R, Herron AR, Lowry AS, et al. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol. 2006;97:532-537.
7. Nakano Y, Niida S, Dote K, et al. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol. 2004;43:818-825.
8. Xu J, Cui G, Esmailian F, et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation. 2004;109:363-368.
9. Gramley F, Lorenzen J, Plisiene J, et al. Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation. J Cardiovasc Electrophysiol. 2007;18:1076-1082.
10. Fu X, Kassim SY, Parks WC, et al. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem. 2001;276:41279-41287.
11. Fu X, Kassim SY, Parks WC, et al. Hypochlorous acid generated by myeloperoxidase modifies adjacent tryptophan and glycine residues in the catalytic domain of matrix metalloproteinase-7 (matrilysin): an oxidative mechanism for restraining proteolytic activity during inflammation. J Biol Chem. 2003;278:28403-28409.
12. Tang RB, Dong JZ, Zhao WD, et al. Unconscious sedation/analgesia with propofol versus conscious sedation with fentanyl/midazolam for catheter ablation of atrial fibrillation: a prospective, randomized study. Chin Med J (Engl). 2007;120:2036-2038.
13. Liu X, Dong J, Mavrakis HE, et al. Achievement of pulmonary vein isolation in patients undergoing circumferential pulmonary vein ablation: a randomized comparison between two different isolation approaches. J Cardiovasc Electrophysiol. 2006;17:1263-1270.
14. Shiroshita-Takeshita A, Brundel BJ, Nattel S. Atrial fibrillation: basic mechanisms, remodeling and triggers. J Interv Card Electrophysiol. 2005;13:181-193.
15. Rudolph V, Andrié RP, Rudolph TK, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med. 2010;16:470-474.
16. Friedrichs K, Baldus S, Klinke A. Fibrosis in atrial fibrillation-role of reactive species and MPO. Front Physiol. 2012;3:214.
17. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J. 2006;27:136-149.
18. Madrid AH. C-reactive protein and atrial fibrillation. An old marker looking for a new target. Rev Esp Cardiol. 2006;59:94-98.
19. Korantzopoulos P, Kolettis TM, Galaris D, et al. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol. 2007;115:135-143.
20. Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96:1180-1184.
21. Podrez EA, Schmitt D, Hoff HF, et al. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 1999;103:1547-1560.
22. Hochholzer W, Morrow DA, Giugliano RP. Novel biomarkers in cardiovascular disease: update 2010. Am Heart J. 2010;160:583-594.
23. Lau D, Mollnau H, Eiserich JP, et al. Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc Natl Acad Sci U S A. 2005;102:431-436.
24. Harper L, Savage CO. Pathogenesis of ANCA-associated systemic vasculitis. J Pathol. 2000;190:349-359.
25. Rarok AA, Limburg PC, Kallenberg CG. Neutrophil-activating potential of antineutrophil cytoplasm autoantibodies. J Leukoc Biol. 2003;74:3-15.
26. Wazni O, Martin DO, Marrouche NF, et al. C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion. Heart. 2005;91:1303-1305.
27. Mocatta TJ, Pilbrow AP, Cameron VA, et al. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol. 2007;49:1993-2000.
28. Fazio S, Palmieri EA, Lombardi G, et al. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res. 2004;59:31-50.
29. Sauer WH, McKernan ML, Lin D, et al. Clinical predictors and outcomes associated with acute return of pulmonary vein conduction during pulmonary vein isolation for treatment of atrial fibrillation. Heart Rhythm. 2006;3:1024-1028.
30. Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol. 2003;42:185-197.